青少年和青年急性淋巴细胞白血病的治疗模式与结局:一项基于人群的研究
该研究利用加州癌症登记处数据,描述2004至2014年确诊的1473例青少年和青年(15-39岁)急性淋巴细胞白血病患者的治疗模式和结局。67.7%在成人机构治疗,其中24.8%接受儿科方案、40.7%在NCI指定中心治疗。在多变量分析中,儿科机构一线治疗(OS HR=0.53,95%CI 0.37-0.76)和NCI/COG中心治疗(OS HR=0.80,95%CI 0.66-0.96)与显著更优的生存相关。作者认为应考虑在儿科和/或NCI/COG指定癌症中心进行一线治疗。
要点
- 67.7%的青少年和青年ALL患者在成人机构接受治疗,其中多数在社区机构。
- 儿科机构一线治疗与更优的总生存(HR=0.53)和白血病特异性生存(HR=0.51)相关。
- NCI/COG指定中心治疗与更优的总生存(HR=0.80)和白血病特异性生存(HR=0.80)相关。
核心结论
- 在成人机构治疗的青少年和青年ALL患者中,接受儿科或成人ALL方案者的结局无差异。
- 作者认为,鉴于潜在的生存获益,应考虑在儿科和/或NCI/COG指定癌症中心对青少年和青年ALL进行一线治疗。
研究设计与样本
- 基于加州癌症登记处的基于人群的研究,纳入2004年至2014年确诊的1473例15-39岁急性淋巴细胞白血病患者。
- 收集社会人口学、治疗地点和一线治疗信息,使用Cox回归模型评估治疗机构与方案和总生存及白血病特异性生存的关联。
主要发现
- 1473例中67.7%在成人机构治疗,其中24.8%接受儿科ALL方案,40.7%在NCI指定中心治疗。
- 儿科机构 vs 成人机构一线治疗:总生存HR=0.53(95%CI 0.37-0.76),白血病特异性生存HR=0.51(95%CI 0.35-0.74)。
- NCI/COG中心 vs 非NCI/COG中心治疗:总生存HR=0.80(95%CI 0.66-0.96),白血病特异性生存HR=0.80(95%CI 0.65-0.97)。
- 在成人机构治疗的患者中,接受儿科ALL方案与成人ALL方案者的结局无差异。
- 在年轻青少年和青年(<25岁)中分析结果相似。
临床怎么用
- 作者认为,鉴于潜在的生存获益,应考虑在儿科和/或NCI/COG指定癌症中心对青少年和青年ALL进行一线治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adolescents and young adults (AYAs, 15-39 years) with acute lymphoblastic leukemia (ALL) represent a heterogeneous population who receive care in pediatric or adult cancer settings. Using the California Cancer Registry, we describe AYA ALL patterns of care and outcomes over the past decade. Sociodemographics, treatment location, and front-line therapies administered to AYAs diagnosed with ALL between 2004 and 2014 were obtained. Cox regression models evaluated associations between ALL setting and regimen and overall survival (OS) and leukemia-specific survival (LSS) for the entire cohort, younger AYA (<25 years), and AYAs treated in the adult cancer setting only. Of 1473 cases, 67.7% were treated in an adult setting; of these, 24.8% received a pediatric ALL regimen and 40.7% were treated at a National Cancer Institute (NCI)-designated center. In multivariable analyses, front-line treatment in a pediatric (vs adult) setting (OS HR = 0.53, 95% confidence interval [CI], 0.37-0.76; LSS HR = 0.51, 95% CI, 0.35-0.74) and at an NCI/Children's Oncology Group (COG) center (OS HR = 0.80, 95% CI, 0.66-0.96; LSS HR = 0.80, 95% CI, 0.65-0.97) were associated with significantly superior survival. Results were similar when analyses were limited to younger AYAs. Outcomes for AYAs treated in an adult setting did not differ following front-line pediatric or adult ALL regimens. Our population-level findings demonstrate that two-thirds of AYAs with newly diagnosed ALL are treated in an adult cancer setting, with the majority receiving care in community settings. Given the potential survival benefits, front-line treatment of AYA ALL at pediatric and/or NCI/COG-designated cancer centers should be considered.
引用
- Muffly L, Alvarez E, Lichtensztajn D, et al. Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. Blood Adv. 2018. PMID: 29669756. doi:10.1182/bloodadvances.2017014944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。